130 related articles for article (PubMed ID: 11022271)
1. Local nasal immunotherapy: efficacy and tolerability of two different administration schedules in grass pollen rhinitis.
Senna GE; Andri G; Dama AR; Falagiani P; Andri L
Allergol Immunopathol (Madr); 2000; 28(4):238-42. PubMed ID: 11022271
[TBL] [Abstract][Full Text] [Related]
2. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study.
Hordijk GJ; Antvelink JB; Luwema RA
Allergol Immunopathol (Madr); 1998; 26(5):234-40. PubMed ID: 9885731
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and tolerability of a steady dosage schedule of local nasal immunotherapy. Results of preseasonal treatment in grass pollen rhinitis.
Bertoni M; Cosmi F; Bianchi I; Di Berardino L
Ann Allergy Asthma Immunol; 1999 Jan; 82(1):47-51. PubMed ID: 9988206
[TBL] [Abstract][Full Text] [Related]
4. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually.
Panzner P; Petrás M; Sýkora T; Lesná I
Respir Med; 2008 Sep; 102(9):1296-304. PubMed ID: 18585908
[TBL] [Abstract][Full Text] [Related]
5. Cluster immunotherapy with a glutaraldehyde-modified mixture of grasses results in an improvement in specific nasal provocation tests in less than 2.5 months of treatment.
Subiza J; Feliú A; Subiza JL; Uhlig J; Fernández-Caldas E
Clin Exp Allergy; 2008 Jun; 38(6):987-94. PubMed ID: 18445082
[TBL] [Abstract][Full Text] [Related]
6. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
7. Monoid sublingual immunotherapy.
Palma-Carlos AG; Santos AS; Branco-Ferreira M; Pregal AL; Palma-Carlos ML
Eur Ann Allergy Clin Immunol; 2006 Mar; 38(3):87-9. PubMed ID: 16752693
[TBL] [Abstract][Full Text] [Related]
8. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
[TBL] [Abstract][Full Text] [Related]
10. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage.
Durham SR; Riis B
Allergy; 2007 Aug; 62(8):954-7. PubMed ID: 17620075
[TBL] [Abstract][Full Text] [Related]
11. Nasal immunotherapy at constant dosage: a double-blind, placebo-controlled study in grass-allergic rhinoconjunctivitis.
Pocobelli D; Del Bono A; Venuti L; Falagiani P; Venuti A
J Investig Allergol Clin Immunol; 2001; 11(2):79-88. PubMed ID: 11642577
[TBL] [Abstract][Full Text] [Related]
12. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.
Rolinck-Werninghaus C; Wolf H; Liebke C; Baars JC; Lange J; Kopp MV; Hammermann J; Leupold W; Bartels P; Gruebl A; Bauer CP; Schnitker J; Wahn U; Niggemann B
Allergy; 2004 Dec; 59(12):1285-93. PubMed ID: 15507097
[TBL] [Abstract][Full Text] [Related]
13. Short-term efficacy of nasal immunotherapy.
Palma-Carlos AG; Santos AS; Pregal A
Allerg Immunol (Paris); 1998 Jan; 30(1):14-7. PubMed ID: 9503098
[TBL] [Abstract][Full Text] [Related]
14. Preventive symptomatic immunotherapy versus placebo in seasonal rhinitis due to grasses in children and to Parietaria in adult patients.
Troise C; Bignardi D; Modena P; Pissacroia C; Di Berardino F
Allerg Immunol (Paris); 2000 Jun; 32(6):246-9. PubMed ID: 10971859
[TBL] [Abstract][Full Text] [Related]
15. The effects of short-term immunotherapy using molecular standardized grass and rye allergens compared with symptomatic drug treatment on rhinoconjunctivitis symptoms, skin sensitivity, and specific nasal reactivity.
Klimek L; Mewes T; Wolf H; Hansen I; Schnitker J; Mann WJ
Otolaryngol Head Neck Surg; 2005 Oct; 133(4):538-43. PubMed ID: 16213926
[TBL] [Abstract][Full Text] [Related]
16. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care.
Röder E; Berger MY; Hop WC; Bernsen RM; de Groot H; Gerth van Wijk R
J Allergy Clin Immunol; 2007 Apr; 119(4):892-8. PubMed ID: 17321581
[TBL] [Abstract][Full Text] [Related]
17. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial.
Kleine-Tebbe J; Ribel M; Herold DA
Allergy; 2006 Feb; 61(2):181-4. PubMed ID: 16409193
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
Bufe A; Ziegler-Kirbach E; Stoeckmann E; Heidemann P; Gehlhar K; Holland-Letz T; Braun W
Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
[TBL] [Abstract][Full Text] [Related]
19. [Cluster-immunotherapy in seasonal allergic rhinitis: safety aspects of induction therapy with depot allergoids (Purethal)].
Hansen I; Hörmann K; Stuck BA; Schneider-Gêne S; Mösges R; Klimek L
Laryngorhinootologie; 2003 Aug; 82(8):558-63. PubMed ID: 12915987
[TBL] [Abstract][Full Text] [Related]
20. Safety of two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma patients sensitized to inhalant allergens.
Pfaar O; Klimek L; Fischer I; Sieber J; Amoroso S; Moreno Aguilar C; Shah K; Mösges R
Int Arch Allergy Immunol; 2009; 150(1):102-8. PubMed ID: 19339808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
